Dr.Reddy's Laboratories Ltd (REDY.NS)

REDY.NS on National Stock Exchange of India

3,349.05INR
28 Feb 2015
Change (% chg)

Rs71.00 (+2.17%)
Prev Close
Rs3,278.05
Open
Rs3,284.60
Day's High
Rs3,371.35
Day's Low
Rs3,260.10
Volume
106,206
Avg. Vol
354,667
52-wk High
Rs3,666.25
52-wk Low
Rs2,246.50

REDY.NS

Chart for REDY.NS

About

Dr. Reddy’s Laboratories Limited (DRL) is an integrated global pharmaceutical company. The Company operates in three segments: Global Generics segment, which includes its prescription and over-the-counter (OTC) drug products business; Pharmaceutical Services and Active Ingredients (PSAI) segment, which consists of its active... (more)

Overall

Beta: 0.31
Market Cap(Mil.): Rs558,513.31
Shares Outstanding(Mil.): 170.38
Dividend: 18.00
Yield (%): 0.55

Financials

  REDY.NS Industry Sector
P/E (TTM): 159.37 38.87 40.17
EPS (TTM): 20.57 -- --
ROI: -- 16.97 16.27
ROE: -- 17.50 17.24
Search Stocks

Indian shares continue to fall ahead of RBI review

MUMBAI, Feb 2 - Indian shares fell on Monday, continuing their retreat from record highs hit last week as blue-chips including Dr.Reddy's Laboratories extended falls after disappointing earnings, while caution prevailed a day before the central bank's policy review.

02 Feb 2015

BUZZ-India's Dr Reddy's falls; Credit Suisse cuts to "neutral"

** Delay in monetisation of key drugs such as Nexium and Copaxone, which implies low-teen FY16 EPS growth - Credit Suisse

30 Jan 2015

BUZZ-India's Dr.Reddy's falls; Health Canada quarantines products from Srikakulam plant

** Dr.Reddy's Laboratories shares fall 1.2 pct ** Canadian importers agree to quarantine products from Dr.Reddy's Srikakulam plant and Ipca Laboratories' Pithampur facility, Health Canada says (http://bit.ly/1HyUTK4) ** Quarantine request due to data integrity concerns, Canadian drug regulator adds ** Continued concerns that sales in Russia may be impacted due to brewing financial crisis in the region also weigh (Reuters Messaging: abhishek.vishnoi.thomsonreuters.com@reuters.net)

24 Dec 2014

Dr Reddy's Labs gains; Morgan Stanley upgrades to 'overweight'

Shares of India's Dr Reddy's Laboratories gain 0.9 percent.

05 Nov 2014

MARKET EYE-India's Dr Reddy's Labs gains; Morgan Stanley upgrades to 'overweight'

* Shares of India's Dr Reddy's Laboratories gain 0.9 percent. * Morgan Stanley upgrades the stock to "overweight" from "equal-weight"; raises price target to 3,875 rupees from 3,049 rupees. * Says drugmaker's U.S. pipeline outlook has strengthened and valuations appears to be reasonable. * "We expect a better outlook for FY16 and FY17 as underlined by improving India, and US businesses," it said. (indulal.p@thomsonreuters.com/indulal.p.thomsonreuters.com@reut ers.net)

05 Nov 2014

Earnings vs. Estimates

Search Stocks